202 related articles for article (PubMed ID: 26408741)
1. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
[TBL] [Abstract][Full Text] [Related]
2. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
3. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
[TBL] [Abstract][Full Text] [Related]
4. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
5. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia.
Styczynski J; Toporski J; Wysocki M; Debski R; Chybicka A; Boruczkowski D; Wachowiak J; Wojcik B; Kowalczyk J; Gil L; Balwierz W; Matysiak M; Krawczuk-Rybak M; Balcerska A; Sonta-Jakimczyk D
Anticancer Res; 2007; 27(3B):1547-51. PubMed ID: 17595774
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.
Styczynski J; Wysocki M; Dluzniewska A; Juraszewska E; Balwierz W; Czyzewski K; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Stanczak E; Malinowska I; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Kapuscinska L; Szczepanek J; Kolodziej B; Rafinska B; Kubicka M
Anticancer Res; 2008; 28(3B):1927-31. PubMed ID: 18630483
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis.
Styczynski J; Wysocki M
Pediatr Blood Cancer; 2004 Feb; 42(2):195-9. PubMed ID: 14752887
[TBL] [Abstract][Full Text] [Related]
10. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
11. Individual tumor response testing in multiple relapsed acute myeloid leukemia in children.
Styczynski J; Piatkowska M; Czyzewski K; Pogorzala M; Wysocki M
Anticancer Res; 2013 Mar; 33(3):1189-93. PubMed ID: 23482801
[TBL] [Abstract][Full Text] [Related]
12. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
[TBL] [Abstract][Full Text] [Related]
13. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
[TBL] [Abstract][Full Text] [Related]
15. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G; Thörn I; Sundström C; Frost BM; Flaegstad T; Heyman M; Jonsson OG; Harila-Saari A; Madsen HO; Porwit A; Schmiegelow K; Söderhäll S; Wesenberg F; Vettenranta K; Larsson R; Forestier E
Leuk Res; 2011 Apr; 35(4):472-8. PubMed ID: 20961616
[TBL] [Abstract][Full Text] [Related]
16. In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Styczynski J; Wysocki M; Debski R; Czyzewski K; Balwierz W; Juraszewska E; Matysiak M; Malinowska I; Stanczak E; Sońta-Jakimczyk D; Szczepanski T; Wachowiak J; Konatkowska B; Balcerska A; Ploszynska A; Kowalczyk J; Stefaniak J; Badowska W; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M
Neoplasma; 2005; 52(1):74-8. PubMed ID: 15739031
[TBL] [Abstract][Full Text] [Related]
17. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
Styczynski J; Koltan A; Wysocki M
Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
[TBL] [Abstract][Full Text] [Related]
18. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
[TBL] [Abstract][Full Text] [Related]
19. Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.
Hongo T; Okada S; Inoue N; Yamada S; Yajima S; Watanabe C; Fujii Y; Horikoshi Y
Int J Hematol; 2002 Oct; 76(3):251-9. PubMed ID: 12416736
[TBL] [Abstract][Full Text] [Related]
20. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
